TALPHERA, INC. (TLPH) - 10-K Filing Summary
Business Context and Reporting Period
Company: Talphera, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Talphera is a specialty pharmaceutical company focused on developing therapies for medically supervised settings. Its primary asset is Niyad (nafamostat mesylate), a regional anticoagulant for continuous renal replacement therapy (CRRT), currently in a Phase 3 registrational trial (NEPHRO CRRT). The company also holds rights to LTX-608 (IV infusion nafamostat) and is evaluating the discontinuation of pre-filled syringe candidates (Fedsyra/Phenylephrine). The company divested its DSUVIA business in 2023, which is now reported as discontinued operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $28,000 (Non-cash) | $0 |
| Net Loss | $(14.3) million | $(13.0) million |
| Operating Expenses | $13.5 million | $15.3 million |
| Cash & Short-Term Investments | $20.4 million | $8.9 million |
| Accumulated Deficit | $(471.5) million | $(457.2) million |
| Outstanding Shares | ~49.3 million | ~17.0 million |
Note: Revenue consists of non-cash revenue related to the sale of future payments agreement with XOMA. The company has not generated significant product revenue.
Material Changes vs. Prior Period
- Capital Raise: The company significantly increased its cash position from $8.9 million to $20.4 million through private placements in April and September 2025, issuing common stock and pre-funded warrants. This resulted in a substantial increase in outstanding shares (from ~17M to ~49M).
- Expense Reduction: Total operating expenses decreased by approximately $1.7 million (11%) year-over-year. Research and Development (R&D) expenses dropped 10% to $6.0 million, and Selling, General, and Administrative (SG&A) expenses dropped 12% to $7.5 million, partly due to the Board of Directors foregoing cash compensation through September 2025.
- Warrant Liability: The fair value of warrant liabilities increased by $1.3 million in 2025, contributing to a net loss increase in "Other (expense) income" compared to 2024.
- Discontinued Operations: The DSUVIA business continues to be reported as discontinued. In 2025, the partner (Alora) requested withdrawal of the DSUVIA NDA and discontinued non-DoD sales efforts.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states there is substantial doubt regarding the company's ability to continue as a going concern. Management expects to need additional capital within the next 12 months to fund operations and the Niyad clinical trial.
- Clinical Trial Status: The NEPHRO CRRT study for Niyad is ongoing with completion expected in 2026. Enrollment has been slower than expected. A subsequent event (March 2026) noted the enrollment of 35 patients, triggering a third closing of the April 2025 private placement.
- Nasdaq Compliance: On March 11, 2026, the company received notice from Nasdaq of non-compliance with the Minimum Bid Price Rule ($1.00). The company has 180 days to regain compliance or face potential delisting.
- Supply Chain Risks: The company relies on single-source suppliers in Asia (Japan for active ingredient, China for finished product) for Niyad. Tariffs and trade restrictions pose significant risks to cost and supply continuity.
- Intellectual Property: An ownership change in September 2025 triggered limitations on the use of Net Operating Loss (NOL) carryforwards, resulting in the expiration of approximately $102.2 million in federal NOLs and $7.5 million in R&D credits.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and the 12-month funding gap.
- Nasdaq Status: Monitor the stock price to determine if the company will meet the $1.00 minimum bid price requirement or if a reverse stock split is necessary to avoid delisting.
- Clinical Milestones: Confirm the progress of the NEPHRO CRRT trial enrollment and the timeline for the primary endpoint readout, which is critical for the contingent funding in the September 2025 private placement.
- Supply Chain Mitigation: Assess the company's progress in securing backup manufacturers outside of Asia to mitigate tariff and geopolitical risks.
- DSUVIA Liability: Review the status of the $6.5 million liability related to the sale of future payments to XOMA, given the partner's withdrawal of the NDA and lack of DoD orders.